BR100 Increased By (0.52%)
BR30 Increased By (0.44%)
KSE100 Increased By (0.46%)
KSE30 Increased By (0.58%)
BECO 5.67 Decreased By ▼ -0.06 (-1.05%)
BML 57.05 Decreased By ▼ -0.25 (-0.44%)
BOP 36.85 Increased By ▲ 0.08 (0.22%)
CNERGY 8.32 Decreased By ▼ -0.07 (-0.83%)
DCL 11.90 Decreased By ▼ -0.14 (-1.16%)
FCCL 58.66 Increased By ▲ 0.05 (0.09%)
FCSC 5.09 Increased By ▲ 0.08 (1.6%)
FFL 18.12 Increased By ▲ 0.18 (1%)
FNEL 1.26 No Change ▼ 0.00 (0%)
HUMNL 11.28 Decreased By ▼ -0.14 (-1.23%)
KEL 8.24 Decreased By ▼ -0.05 (-0.6%)
KOSM 6.54 Decreased By ▼ -0.08 (-1.21%)
MLCF 107.17 Decreased By ▼ -1.12 (-1.03%)
NBP 208.80 Increased By ▲ 2.76 (1.34%)
PACE 11.18 Increased By ▲ 0.01 (0.09%)
PAEL 45.39 Increased By ▲ 0.04 (0.09%)
PIAHCLA 30.31 Decreased By ▼ -0.46 (-1.49%)
PIBTL 18.87 Decreased By ▼ -0.19 (-1%)
PPL 248.71 Increased By ▲ 2.76 (1.12%)
PRL 36.29 Increased By ▲ 0.21 (0.58%)
PTC 74.01 Increased By ▲ 1.65 (2.28%)
SEARL 96.13 Decreased By ▼ -0.54 (-0.56%)
SSGC 31.37 Decreased By ▼ -0.30 (-0.95%)
TELE 9.21 Decreased By ▼ -0.06 (-0.65%)
THCCL 68.04 Increased By ▲ 0.23 (0.34%)
TPLP 11.64 Increased By ▲ 0.41 (3.65%)
TREET 25.72 Decreased By ▼ -0.17 (-0.66%)
TRG 67.62 Decreased By ▼ -0.22 (-0.32%)
WAVES 11.25 Increased By ▲ 0.27 (2.46%)
WTL 1.28 No Change ▼ 0.00 (0%)
By

SYDNEY: Australia has secured access to a "promising" potential coronavirus vaccine, the prime minister announced Tuesday, saying the country would manufacture it and offer free doses to the entire population.

Prime Minister Scott Morrison said Australia had reached a deal with Swedish-British pharmaceutical company AstraZeneca to receive the Covid-19 vaccine it is developing with Oxford University.

"The Oxford vaccine is one of the most advanced and promising in the world, and under this deal we have secured early access for every Australian," he said.

"If this vaccine proves successful we will manufacture and supply vaccines straight away under our own steam and make it free for 25 million Australians."

The Oxford vaccine is one of five globally in Phase 3 efficacy trials, and researchers hope to have results by the end of the year.

Comments

Comments are closed for this article.